Fatty Liver Disease

Research on metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD/NASH. Includes hepatic steatosis, inflammation, fibrosis, and their treatment.

Quick Answer

What it is

Research on metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD/NASH. Includes hepatic steatosis, inflammation, fibrosis, and their treatment.

Key findings

  • Grade A: Liver Fat Reduction (Retatrutide (GLP-3 Triple Agonist))

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

ℹ️ Quick Facts

Quick Facts: Fatty Liver Disease

  • Supplements Studied:1
1 supps · 1 outcomes

Detailed Outcomes

A
Liver Fat Reduction
Phase 2a MASLD (n=98): 82-86% relative reduction in liver fat at 48 weeks with 8-12mg. 89-93% achieved normal liver fat (<5%). Driven by glucagon receptor activation promoting hepatic lipid oxidation.
large↓Improves

Research Citations (61)

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
(2026)
PMID: 41090431
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
(2025)
PMID: 40609566
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
(2025)
PMID: 39761578
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
(2025)
PMID: 39968298
What is the pipeline for future medications for obesity?
(2025)
PMID: 38302593
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
(2025)
PMID: 40489581
Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.
(2025)
PMID: 40554267
Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.
(2025)
PMID: 41025003
Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.
(2025)
PMID: 41056349
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
(2025)
PMID: 39817343

Related Conditions